A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
暂无分享,去创建一个
J. Kirkwood | K. Lewis | W. Samlowski | L. Cranmer | E. Whitman | R. Gonzales | P. Bartels | D. Lawson | D. Alexandrescu | A. Keating | J. Catlett | T. Drake